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Gene expression data is widely used in various post genomic analyses. The data is often probed using microarrays due to their ability
to simultaneously measure the expressions of thousands of genes. The expression data, however, contains signiﬁcant numbers of missing
values, which can impact on subsequent biological analysis. To minimize the impact of these missing values, several imputation algo-
rithms including Collateral Missing Value Estimation (CMVE), Bayesian Principal Component Analysis (BPCA), Least Square Impute
(LSImpute), Local Least Square Impute (LLSImpute), and K-Nearest Neighbour (KNN) have been proposed. These algorithms, however,
exploit either only the global or local correlation structure of the data, which normally can lead to higher estimation errors. This paper
presents an Ameliorative Missing Value Imputation (AMVI) technique which has ability to exploit global/local and positive/negative cor-
relations in a given dataset by automatic selection of the optimal number of predictor genes k using a wrapper non-parametric method
based on Monte Carlo simulations. The AMVI technique has CMVE strategy at its core because CMVE has demonstrated improved
performance compared to both low variance methods like BPCA, LLSImpute, and high variance methods such as KNN and ZeroIm-
pute, as CMVE exploits positive/negative correlations. The performance of AMVI is compared with CMVE, BPCA, LLSImpute, and
KNN by randomly removing between 1% and 15% missing values in eight diﬀerent ovarian, breast cancer and yeast datasets. Together
with the standard NRMS error metric, the True Positive (TP) rate of the signiﬁcant genes selection, biological signiﬁcance of the selected
genes and the statistical signiﬁcance test results are presented to investigate the impact of missing values on subsequent biological anal-
ysis. The enhanced performance of AMVI was demonstrated by its lower NRMS error, improved TP rate, bio signiﬁcance of the selected
genes and statistical signiﬁcance test results, when compared with the aforementioned imputation methods across all the datasets. The
results show that AMVI adapted to the latent correlation structure of the data and proved to be an eﬀective and robust approach com-
pared with the trial and error methodology for selecting k. The results conﬁrmed that AMVI can be successfully applied to accurately
impute missing values prior to any microarray data analysis.
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Microarrays gene expression data are used in a wide
range of biological applications from the study of human
tumours [1,2] to yeast sporulation [3] because of their abil-
ity to measure the gene expressions for many thousands of
genes under a variety of conditions. This expression data
are subsequently applied in a range of applications from
diagnosis to drug discovery [4], all of which to some degree
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machine learning methods [5–7] such as, class prediction
[9,10], clustering [11], gene regulatory network reconstruc-
tion [12], and data dimension reduction [8]. Despite wide
usage, microarray data frequently contain at least 5% miss-
ing values and in most datasets, at least 60% of genes have
one or more missing values [13]. Once microarray images
have been scanned, the problematic spots are identiﬁed as
missing values with the reason for such occurrences include
slide scratches, spotting problems, blemishes on the chip,
hybridization error, image corruption or simply dust on
the slide [14]. Sometimes for instance, a background color
has a higher intensity than a foreground color due to bleed-
ing from neighboring spots, while background subtraction
may also produce negative values which are subsequently
marked as missing. It is important to highlight that the def-
inition of missing values used in this paper is diﬀerent from
the present/absent ﬂag in GeneChip data (Aﬀymetrix soft-
ware), which indicates whether or not genes are detectable
at signiﬁcant levels [15].
As previously alluded to, the missing values can seri-
ously impact upon subsequent data analysis involving for
example, signiﬁcant class prediction, gene selection, gene
regulatory network reconstruction [16] and clustering algo-
rithms such as Support Vector Machines (SVM), Neural
Networks (NN), t-test [17], and Hierarchical Clustering
[18,19]. Several approaches to impute missing values have
been proposed with the simplest being either the repetition
of the experiment, though this is often not feasible for eco-
nomic reasons or ignoring samples containing missing val-
ues, but again this is not recommended because there may
only be a limited number of samples available. Other alter-
natives include, row average/median impute (replacement
by the corresponding row average/median) and zero
impute (replace the missing values by zero) though these
are high variance approaches as neither takes advantage
of inherent data correlations, so leading to higher estima-
tion errors [20]. A rational strategy is to accurately estimate
the missing values, since if the latent correlations in the
data are exploited then the missing value prediction errors
will be signiﬁcantly reduced [18,21,22]. This has been the
catalyst for a myriad of imputation techniques including
Collateral Missing Value Imputation (CMVE) [23], K-Near-
est Neighbor (KNN), Least Square Imputation (LSImpute)
[22], Local LSImpute (LLSImpute) [10] and Bayesian PCA
(BPCA) [14]. The resulting estimation errors can still be
high, as certain algorithms chieﬂy focus only on global cor-
relation (BPCA), while others exploit local correlations in
the data structure (KNN) by using a ﬁxed number of pre-
dictor genes. This provided the motivation for the develop-
ment of new generic techniques that minimize prediction
errors by optimizing the number of predictor genes. In
addition, traditionally the comparative imputation perfor-
mances of CMVE, BPCA, LSImpute, LLSImpute, and
KNN have been evaluated using a Normalized Root Mean
Square (NRMS) error measure, which does not fully eluci-
date the impact of estimation on any subsequent analysislike signiﬁcant gene selection where a biological interpreta-
tion of diﬀerent genes for diﬀerent diseases is mandated. So
a more rigorous analysis of each gene aﬀected by the miss-
ing values is required.
This paper presents Ameliorative Missing Value Imputa-
tion (AMVI) algorithm that employs a combination of cor-
related genes to estimate missing values by multiple
imputation matrices. The basis of AMVI is the CMVE tech-
nique that has proven both theoretically and empirically [23]
to be a better estimator compared with established algo-
rithms such as KNN, LLSImpute and BPCA. Like KNN,
however, CMVE does not automatically determine the opti-
mal number of predictor genes k from the dataset, which can
lead to higher estimation errors. For data with a local corre-
lation structure, if a large k-value is used then it may include
genes which have no correlation with the gene that has miss-
ing values. Similarly, if data has a global correlation struc-
ture, then a small value of k ignores correlated genes in
the prediction, again resulting in a higher estimation error,
so it is highly desirable to calculate the best value of k based
upon the underlying correlation structure of the data.
LLSImpute automatically determines k, though since this
method is based on LS regression it provides coarser esti-
mates and manifests in higher imputation errors. AMVI
uses CMVE at its core and incorporates a wrapper non-
parametric estimator based on Monte Carlo simulations
[24] to automatically determine k, thereby combining the
intrinsic beneﬁts of CMVE with a strategy to automatically
estimate the optimal number of predictor genes, as by
LLSImpute. The reason to use this particular strategy to
estimate k is explained in Section 3.
The estimation performance of AMVI has been rigor-
ously tested and compared with the aforementioned well-
established and recently proposed, imputation techniques,
namely CMVE, KNN, LLSImpute, and BPCA in predict-
ing randomly introduced missing values with probabilities
ranging from 0.01 to 0.15 for eight diﬀerent ovarian, breast
cancer [3,25,26], and yeast saccharomyces cerevisiae data-
sets [27]. In particular, the study compared the impact of
estimation on signiﬁcant gene selection using Between Sum
of Squares to Within Sum of Squares (BSS/WSS) method,
where AMVI demonstrated enhanced gene selection capa-
bility for breast and ovarian cancer (Homo sapiens), and
yeast (simple eukaryote) datasets. The biological analysis
of the selected gene demonstrated that the AMVI selected
many important expressed genes, which were ignored by
the other imputation methods. In addition, the results were
cross validated using non-parametric Wilcoxon Ranksum
Signiﬁcance test [28], where the results again, mandated
the improved performance of AMVI. For completeness,
results were also compared using the standard NRMS error
[29] metric to quantitatively assess the estimation perfor-
mance of each imputation method, with results once again
demonstrated improved accuracy and robustness of AMVI
over a wide range of missing values.
The remainder of the paper is organized as follows:
Section 2 brieﬂy reviews the main properties of existing
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rithm and its underlying theory are presented in Section 3. A
comprehensive discussion and analysis of the results, includ-
ing their biological signiﬁcance is presented in Section 4,
with some conclusions are provided in Section 5.
2. Review of existing imputation techniques
In describing various imputation techniques, the follow-
ing nomenclature is adopted. Microarray gene expression
matrix Y 2 Rmn contains m genes and n samples. In Y,
every gene i is represented by gi, so Y in n experiments is
arranged as Y ¼ ½g1 . . . gmT 2 Rmn. A missing value in
gene i for sample j is expressed as Y ði; jÞ ¼ giðjÞ ¼ N.
The following paragraph provides a brief review of the
main features of KNN, LLSImpute, BPCA and CMVE,
which are the algorithms used in this paper to compare
with the performance of AMVI.
KNN [20] estimates missing values by searching for the
k nearest genes using the Euclidean distance function and
then taking the weighted average. The method, however,
does not consider negative correlations [21] and has the
disadvantage of using a predetermined value of kregardless
of the dataset being used. Kim et al. [30] introduced Least
Square (LS) regression based algorithm called LLSImpute
that automatically selects the number of estimator genes k
using an exhaustive search method. The method has shown
to be having lower estimation error than other least square
regression based estimation methods, such as LSImpute
[30]. The BPCA [14] imputation technique uses Bayesian
estimates and Principal Component Analysis to impute
the missing values, though this technique only exploits glo-
bal correlations within the data structure, which can lead
to erroneous estimates if data possesses a strong local cor-
relation [14]. The CMVE algorithm developed by Sehgal
et al. [23] generates multiple estimation matrices using
Non-Negative Least Square (NNLS), Linear Programming
(LP) and LS regression techniques to approximate missing
values. In spite of its enhanced estimation performance
over other algorithms it still relies upon a preset parametric
value of k, which ultimately limits its applicability. While
LLSImpute automatically determines k, it still has least
square regression as its core resulting in higher estimation
errors. This initiated a need for a suitable algorithm to
automatically determine the best value of k, directly from
the correlation structure of the data while concomitantly
providing low estimation errors. Next section presents
the AMVI estimation technique, which combines both
the enhanced estimation capability of CMVE with a new
strategy for deriving the optimal value of k directly from
the correlation structure of the data.
3. Non-parametric Ameliorative Missing Value Imputation
(AMVI)
The AMVI algorithm, which is formally presented in
Fig. 1, imputes missing values in three stages. Firstly, thenumber of estimator genes k is computed using a wrapper
non-parametric algorithm that exploits the correlation struc-
ture of the data. Secondly, the k most correlated genes with
gene gi that contains themissing value are selected for a given
dataset, and ﬁnally gi is approximated using the CMVE ker-
nel with NNLS, LP and LS regression at its core.
To select the number of estimator genes k, a set of vec-
tors v from Y is selected using Monte Carlo Simulation
with uniform distribution for the interval [m,n] [24] where
a statistical conservative value of selection probabil-
ity = 0.05 is chosen [31] as v ¼ ½v1 . . . vnT 2 Rmn (Step 1,
Fig. 1). This is followed by the selection of genes G which
are present in v (Step 2), such as G ¼ ½G1 . . .GnT 2 Rmn
with these values of G treated as missing values and itera-
tively estimated for a range of diﬀerent k values (Step 3).
Finally, the k value which produces the minimum NRMS
error is designated as the optimal value (optk) and used
in the actual estimation of missing value Yij of gene i and
sample j, which involves three estimates U1, U2 and U3
being generated, and the ﬁnal estimate v computed by their
fusion using CMVE (Method Estimate in Fig. 1). To esti-
mate the missing value, for any given data set, the absolute
diagonal covariance C is computed using (1) for a gene vec-
tor gi, which contains an actual missing value, where every
gene except i is iteratively considered as a predictor gene
(x) (Step 1.2 Estimate Method). The covariance function
C is formally deﬁned as:
Cðgi;xÞ ¼
1
ðn 1Þ
Xn
j¼1
ðgiðjÞ  giÞðxj  xÞ ð1Þ
Another option would have been to use Pearson Correla-
tion, though the overall eﬀect is exactly same for normally
distributed data [32]. The genes are then ordered with re-
spect to their covariance values and the ﬁrst optk ranked
covariate genes Roptk are selected, whose expression vectors
have the closest similarity to gene i from Y in all samples
except j (Step 1.4). The LS regression [33] is then applied
to estimate value U1) for Yij (Step 1.5) as:
U1 ¼ aþ bRoptk þ n ð2Þ
where n is the error term that minimizes the variance in the
LS model (parameters a and b). For a single regression, the
estimate of a and b are, respectively, a ¼ gi  b Roptk and
b ¼ IxyIxx where Ixy is the covariance between Roptk and gi
computed using (1) and Ixx ¼ 1n1
Pn
j¼1ðRoptkðjÞ  RoptkÞ2 is
the variance of Roptk with Roptk; where gi being the respec-
tive means of Roptk and gi, The two other missing value esti-
mates U2 and U3 (Step 1.6) are, respectively, given by:
U2 ¼
Xoptk
i¼1
/þ g
Xoptk
i¼1
n2 ð3Þ
U3 ¼
Poptk
i¼1 ð/T  IÞ
optk
þ g ð4Þ
where u is the vector that minimizes n0 in (5), g is the nor-
mal residual and n is the actual residual. These three
Fig. 1. The complete AMVI algorithm.
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The objective is now to ﬁnd a linear combination of models
that best ﬁt Roptk and gi. The objective function in NNLS
minimizes the prediction error n0 using linear programming
(LP) techniques, so that:
n;/; g ¼ minðn0Þ ð5Þ
minðn0Þ is a function that locates the normal vector u with
minimum prediction error n0 and residual g. The value of
n0 in (5) is obtained from:n0 ¼ maxðSV ðRoptk  / giÞÞ ð6Þ
where SV are the singular values of the diﬀerence vector be-
tween the dot product of Roptk and prediction coeﬃcients u
with the gi. The tolerance used in the LP to compute vector
u is given by:
Tol ¼ optk  nmaxðSV ðRoptkÞÞ  N f ð7Þ
where optk is the number of predictor genes computed
by the Non-parametric algorithm using Monte Carlo
simulations, n the number of samples in the dataset and
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formed by:
v ¼ q  U1 þ D  U2 þ K  U3 ð8Þ
where q ¼ D ¼ K ¼ 0:33 ensures an equal weighting to the
respective estimates U1, U2 and U3, which avoids bias being
given towards one particular estimate as each is highly data
dependent. The ﬁnal fused value v has a lower NRMS error
as the imputation matrix U1 uses LS regression, while
matrices U2 and U3 use Non-Negative LS (NNLS).4. Analysis of results and discussion
4.1. Test data
To analyze and compare the performance of the pro-
posed AMVI algorithm with CMVE, BPCA, LLSImpute,
KNN, and ZeroImpute, eight microarray cancer and yeast
datasets from diﬀerent studies on breast, ovarian cancer tis-
sues and yeast Saccharomyces cerevisiae were used. The
rationale for selecting cancer datasets is that generally, can-
cer data lack molecular homogeneity in tumour tissues,
which can result in erroneous results when imputation
methods are applied [15] while the choice of yeast data
was made due to its wide usage by bioinformatics commu-
nity. One of the possible reason of the wide usage of yeast
data could be due its simplest genome in eukaryotic family
(1.2  107 base pairs) [34]. The locally correlated breast
cancer dataset contained 7, 7, 8 samples of BRCA1,
BRCA2, and sporadic mutations (neither BRCA1 nor
BRCA2), respectively [26]. The globally correlated ovarian
cancer dataset contained 16, 16, and 18 samples of
BRCA1, BRCA2, sporadic mutations, respectively [25].
While the yeast data had six samples at diﬀerent time
stamps in each heat shock study. The heat shock response
in yeast was measured at 30 C and 60 C. There were 3225,
6445, and 6130 genes in each sample of breast, ovarian andTrue Positive Rate of Significant Gene
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Fig. 2. TP rate of genes selyeast datasets, after the removal of gene expressions with
more than 20% missing values.
4.2. Analysis of simulation results
This section provides rigorous analysis of empirical
results, which includes validation of imputation strategies
based on gene selection performance, biological signiﬁ-
cance of the selected genes, statistical signiﬁcance test and
standard NRMS error.
4.2.1. Gene selection using BSS/WSS
To cross validate the performance of AMVI on gene
selection BSS/WSS method was used.
The method identiﬁes those genes which concomitantly
have large inter-class variations and small intra-class vari-
ations. For any gene i in Y 2 Rmn, BSS/WSS is calculated
as follows:
BSSðiÞ=WSSðiÞ ¼
PT
t¼1
PQ
q¼1F ðLt ¼ qÞð Y qi  Y iÞ2
PT
t¼1
PQ
q¼1F ðLt ¼ qÞð Y it  Y qiÞ2
; ð9Þ
where T is the training sample size, Q the number of classes
and F() is a Boolean function = 1 if the condition is
TRUE and zero, otherwise. Y j denotes the average expres-
sion level of gene i across all samples and Y qi is the average
expression level of gene i across all samples belonging to
class q. Genes are then ranked by BSS/WSS ratios, from
the highest to the lowest to form a signiﬁcant gene expres-
sion matrix #, where the ﬁrst p genes are selected for sub-
sequent class prediction. To set a benchmark gene set a
set of p genes Gorg was selected from the original data Y
using the BSS/WSS method.
To fully test the robustness of the AMVI algorithm,
experiments were performed for missing values up to
15%, with values being iteratively removed from the origi-
nal gene expression matrix Y. Missing values were then
estimated using KNN, LLSImpute, BPCA, CMVE, ands in Breast Cancer Data
5 10 15
es
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AMVI
ection in breast cancer.
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Fig. 3. True positive rate of genes selection in ovarian cancer.
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were selected using the BSS/WSS method for each esti-
mated matrix. These selected genes were then compared
with Gorg to compute the True Positive (TP) rate.
Fig. 2 plots the TP rate for ﬁrst 1000 signiﬁcant genes in
breast cancer, from which it is clear that AMVI outper-
formed all other comparative methods in terms of estima-
tion quality. The localized correlation structure of this
dataset is conﬁrmed by the generally lower TP rate for
BPCA, which is characterized by exploiting only global
correlation performed worse than a high variance method
such as KNN. CMVE despite using a ﬁxed number
(k = 10) of predictor genes exhibited good performance
as it exploited the underlying local correlation structureFrequency Plot: TP Rate of Significant Genes
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Fig. 4. Accumulated TP rate of the ﬁrst 50 signiﬁcant genes for 1%, 2%, 3of the data. Fig. 3 conﬁrms the consistent performance
improvement of AMVI in terms of TP rate for the ovarian
cancer dataset, especially for higher numbers of missing
values, compared to the other estimation methods, with
interestingly BPCA due to its emphasis on global correla-
tion of the data demonstrated lower error than KNN
and CMVE. The impact of imputation on gene selection
was evaluated by varying the number of signiﬁcance genes
where the results demonstrated similar performance trends.
For example, Figs. 4 and 5 show the accumulated TP rate
for the ﬁrst 50 genes selected for imputation by AMVI,
CMVE, BPCA, LLSImpute, KNN, and ZeroImpute in
seven speciﬁc cases, namely: 1%, 2%, 3%, 4%, 5%, 10%,
and 15% missing values in both the breast and ovarian can- in Breast Cancer Data
33 35 37 39 41 43 45 47 49
KNN
LLSImpute
BPCA
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AMVI
%, 4%, 5%, 10% and 15% missing values in the breast cancer dataset.
Frequency Plot: TP Rate of Significant Genes in Ovarian Cancer Data
0
1
2
3
4
5
6
7
1 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49
Gene ID
G
en
e 
Se
le
ct
io
n 
Fr
eq
ue
nc
y
KNN
LSImpute
LLSImpute
BPCA
AMVI
3 5 7 9
Fig. 5. Accumulated TP rate of the ﬁrst 50 signiﬁcant genes for 1%, 2%, 3%, 4%, 5%, 10% and 15% missing values in the ovarian cancer dataset.
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performance of AMVI.
The experimental results on yeast data in Fig. 6 demon-
strate that AMVI showed higher TP rate than CMVE,
LLSImpute and KNN. Interestingly, BPCA had lower
error for higher percentage of missing values than AMVI,
though it was not retained for the aforementioned ovarian
and breast cancer data (Figs. 2 and 3). The AMVI, how-
ever, inculcation consistently showed acceptable perfor-
mance for the complete range of missing values in all the
datasets which underpins that AMVI can be used to esti-
mate missing values in gene expression data prior to any
biological analysis.
As mentioned in Section 1 that it is important to study
the selected genes therefore, the study was undertaken onTrue Positive Rate of Significan
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Fig. 6. True positive rate ofcancer data. For the purposes of clarity, the overall trend
of gene selection is shown in Figs. 7 and 8, which both
reveal that certain genes are more aﬀected by missing val-
ues and the subsequent impact of imputation than others,
due to both the location of missing values and diﬀering
variances. For example, Gene ID 28 in Fig. 7 has a low
TP rate being selected only 17 times out of 42 (40% selec-
tion rate) by all imputation techniques other than AMVI,
which had a success rate for this particular gene of 100%
(Fig. 4) compared to 57%, 57%, 28%, 0%, and 0% for
CMVE, LLSImpute, BPCA, KNN and ZeroImpute,
respectively (Fig. 4). Similarly, Gene 6 in Fig. 8 has selec-
tion rate of only 38% and yet was always correctly selected
by AMVI (Fig. 5) due to its better estimation ability. The
same gene had respective TP rates of 57%, 43%, 29%,t Genes in Yeast Data
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genes selection in yeast.
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Fig. 7. Frequency plot for the ﬁrst 50 signiﬁcant genes for 1–15% missing values in the breast cancer data.
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Fig. 8. Frequency plot for the ﬁrst 50 signiﬁcant genes for 1–15% missing values in the ovarian cancer data.
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and KNN (Fig. 5).Table 1
KIAA1025 (KIAA) and Plakophilin2 (PKP2) selection in breast cancer
dataset across the range of missing values
%MV AMVI CMVE LLSImpute BPCA KNN ZeroImpute
1 KIAA KIAA KIAA KIAA
PKP2 PKP2
5 KIAA KIAA KIAA KIAA
PKP2 PKP2
10 KIAA KIAA
PKP2 PKP2
15 KIAA KIAA
PKP2 PKP24.2.2. Biological signiﬁcance of selected genes
In examining diﬀerent datasets, AMVI identiﬁed a num-
ber of genes overlooked by all the other algorithms [35],
which alter expressions in tumor lines and so could be
important in oncogenesis. This set of genes has not only
been selected by BSS/WSS algorithm but has been revali-
dated using the modiﬁed t-test with greedy pairs method
[36]. The revalidation minimizes the bias of the gene selec-
tion strategy towards either a particular imputation tech-
nique or a set of genes.
For example, as the results in Table 1 reveal, the
KIAA1025 protein was not selected when values were
imputed using KNN, LLSImpute, BPCA, CMVE and
ZeroImpute, but had been identiﬁed when gene selection
was preceded by AMVI imputation. This is an important
protein which is co-regulated with estrogen receptors forboth in vivo and clinical data, and is expressed in more than
66% of human breast tumors [37]. Another gene selected by
AMVI across the range of missing values is plakophilin 2
(PKP2) which is a common protein and exhibits a dual
role, appearing as both a constitutive karyoplasmic protein
and a desmosomal plaque component for all the desmo-
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found in breast carcinoma cell lines [38] and furthermore,
because of its signiﬁcance it can serve as a marker for the
identiﬁcation and characterisation of carcinomas derived
either from or corresponding, to simple or complex epithe-
lia [39] (see Table 1).
Similar observations can be made in the study of signif-
icant genes in the ovarian cancer dataset. For instance,
MHC Class II = DQ alpha (MHCa) and MHC Class
II = DQ beta (MHCb) genes are linked to the immune sys-
tem and have been shown to be down-regulated for ovary
syndrome [40]. Also, the allele gene is present at a higher
frequency in patients with malignant melanoma than in
Caucasian controls. These genes help in particular to diag-
nose melanoma patients in the relatively advanced stages of
the disease and/or patients who are more likely to have a
recurrence [41]. The results reveal that these genes have
been correctly identiﬁed by AMVI while being consistently
missed by other imputation methods, especially for higher
numbers of missing values (see Table 2).4.2.3. Signiﬁcance test
This section provides the results of two-sided Wilcoxon
Rank Sum Statistical Signiﬁcance test. The signiﬁcance test
was undertaken, to prove the validity of the estimationTable 2
MHC Class II = DQ alpha (MHCa) and MHC Class II = DQ beta (MHCb)
%MV AMVI CMVE LLSImpu
1 MHCa MHCa MHCa
MHCb
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Fig. 9. Signiﬁcance of similarity between actualaccuracy achieved by diﬀerent imputation methods, with
statistically conservative signiﬁcance level of 0.05 [28].
The rationale behind using this test was that it does not
mandate the data to have equal variances, which is vital
given the variances of data can be disturbed due to errone-
ous estimation, especially in case of ZeroImpute. The null
hypothesis H 0Y  Y est where Y and Yest are the actual and
estimated matrices, respectively, the P-value of the hypoth-
esis is calculated as:
H 0; P -value ¼ 2P rðR > yrÞ ð10Þ
where yr is the sum of the ranks of observations for Y and
R is the corresponding random variable.
AMVI demonstrated best performance for all the three
cases of breast cancer data (BRCA1, BRCA2 and spo-
radic). It is noteworthy that the (1  P) (the null hypothesis
rejection probabilities) values are plotted in Figs. 9–11 for
the sake of clarity. Therefore, the higher (1  P) value rep-
resents more accurate estimation than lower (1  P) values.
The results were signiﬁcant for higher percentage of miss-
ing values where the comparative methods had higher error
rate for large number of missing values. For instance,
LLSImpute had varied performances for diﬀerent range
of missing values and could not maintain it for higher
percentage of missing values (Figs. 9–11). Similarly,selection in ovarian cancer across the range of missing values
te BPCA KNN ZeroImpute
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Fig. 10. Signiﬁcance of similarity between actual BRCA2-breast cancer and estimated data.
Significance Test Results for Sporadic-Breast Cancer Data
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Fig. 11. Signiﬁcance of similarity between actual sporadic-breast cancer and estimated data.
Significance Test Results for BRCA1-Ovarian Cancer Data
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Fig. 12. Signiﬁcance of similarity between actual BRCA1-ovarian cancer and estimated data.
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Significance Test Results for BRCA2-Ovarian Cancer Data
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Fig. 13. Signiﬁcance of similarity between actual BRCA2-ovarian cancer and estimated data.
Significance Test Results for Sporadic-Ovarian Cancer Data
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Fig. 14. Signiﬁcance of similarity between actual sporadic-ovarian cancer and estimated data.
Significance Test Results for Yeast Heat Shock 30 Data
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Fig. 15. Signiﬁcance test results of yeast heat shocked at 30 C.
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error rate, across the range of missing values, highlightingthe need of more accurate estimation methods than simple
strategies. The similar performance improvement was
510 Muhammad Shoaib B. Sehgal et al. / Journal of Biomedical Informatics 41 (2008) 499–514observed when AMVI and comparative methods were
applied to ovarian cancer data (Figs. 12–14). Figs. 15, 16
show the signiﬁcance results of two yeast datasets. The
AMVI method showed lower error than LLSImpute,
KNN and ZeroImpute. As it was observed in case of gene
selection BPCA performed better than AMVI for some
percentage of missing values. BPCA, however, could not
exhibit the same performance for all the other datasets.
The AMVI technique demonstrated stable performance
for all the datasets while again highlighting the need of
fully exploiting the correlation structure of the data for
estimation.
For the sake of completeness, the algorithms were
also compared based on the standard NRMS error.
The next section provides analysis of NRMS error in
detail:Significance Test Results for Yea
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Fig. 16. Signiﬁcance test results o
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Fig. 17. NRMS error in BRCA1 breast cance4.2.4. Calculation of normalized root mean square error
The missing value estimation techniques were also eval-
uated by randomly removing between 1% and 15% values
from the datasets and then computing the imputation error
in terms of the NRMS error H:
H ¼ RMSðY  Y estÞ
RMSðY Þ ð11Þ
where Y is the original data matrix and Yest is the estimated
matrix using AMVI, CMVE, BPCA, LLSImpute, and
KNN, respectively. This particular measure has been used
by Tuikkala et al. [13] and Sehgal et al. [23,29] for error
estimation because H = 1 for zero imputation.
To compare the performance of CMVE, KNN, BPCA
and LLSImpute with AMVI algorithm, k = 10 was used
throughout the experiments. As Troyanskaya et al. [20]st Heat Shock 60 Data
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ues
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r dataset for 1–15% missing valued data.
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range 10–20 and the best estimation results are achieved
in this interval. Similarly, we used k = 10 for CMVE
due to the reason described in [23]. In contrast, LLSIm-
pute determines the value of k using correlation structure
of the data, while AMVI automatically determines theAMVI CMVE B
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Fig. 18. NRMS error in BRCA1 ovarian canc
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Fig. 19. NRMS error in yeast heat shocked daoptimal value of optk using wrapper non-parametric algo-
rithm (see Fig. 1), which exploits the underlying correla-
tion structure of the data due to the reasons underlined
in Section 1.
Figs. 17–20 demonstrate box plots of the NRMS error
for 1–15% missing values for breast, ovarian cancer, andPCA LLSImpute KNN
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er dataset for 1–15% missing valued data.
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Fig. 20. NRMS error in yeast heat shocked data at 60 C for 1–15% missing valued data.
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mance of AMVI in estimating missing values for all types
of experimental data, across the range of missing values.
The imputation results also revealed some interesting
issues. Since, BPCA exploits only global correlation in
the data; all other algorithms had a lower NRMS error
in the case of the BRCA1, a locally correlated breast can-
cer data (Fig. 17), though conversely, when it was used to
estimate the missing values for the datasets possessing
global correlation structure, it performed better than both
KNN and LLSImpute (Fig. 18). The performance of
AMVI was further evaluated on yeast data where the
results again demonstrated that AMVI has lower estima-
tion error rate in terms of NRMS error compared to the
aforementioned imputation strategies (Figs. 19 and 20).
As mentioned earlier, it is highly important that estima-
tion methods should be able to demonstrate lower estima-
tion errors across the range of datasets. For instance,
BPCA method had lower imputation error for ovarian can-
cer (Fig. 17) but showed largest disparity for yeast dataset
(Fig. 19). Similarly, LLSImpute exhibited lower NRMS
error for cancer datasets but could not maintain the same
performance for both yeast datasets (Figs. 19 and 20)
and the error rate was comparable to KNN. The CMVE
(Fig. 17) exhibited lower NRMS error for both types of
cancer data; but it did not maintain this performance when
determining signiﬁcant genes in the ovarian cancer data
(Fig. 3) due to global correlation structure possessed by
the dataset. In contrast, AMVI adapted to the correlationstructure of the data and showed improved performance
for all types of datasets, so endorsing the strategy to com-
pute the optimal number of predictor genes based on the
correlation structure of the data, rather than using a ﬁxed
value.
5. Conclusions
This paper has presented a new Ameliorative Missing
Value Imputation (AMVI) algorithm based on the concept
of automatic estimation of the optimal number of predic-
tor genes for the fusion of multiple imputation matrices.
AMVI has demonstrated a capability to adapt to any type
of data correlation, with experimental results including
the True Positive rate of signiﬁcant genes selection, bio-
logical signiﬁcance analysis of the selected genes, statisti-
cal signiﬁcance test and normalized root mean square
error, proving this algorithm provided lower estimation
error compared with other comparative missing value
imputation techniques, namely CMVE, LLSImpute,
BPCA, KNN, and ZeroImpute. The impact of this
improvement was especially highlighted when signiﬁcant
genes were selected prior to imputation. The reason for
this superior performance is that AMVI combines the
exploitation of global and local correlations in a given
dataset with the automatic selection of the optimal num-
ber of predictor genes k by a wrapper non-parametric
method based on Monte Carlo simulation. This consis-
tently proved to be an eﬀective and robust strategy
Muhammad Shoaib B. Sehgal et al. / Journal of Biomedical Informatics 41 (2008) 499–514 513compared with the trial and error approaches adopted by
CMVE and KNN for selecting k and conﬁrmed
that AMVI can be successfully applied to accurately
impute missing values prior in any microarray data
experiment.Acknowledgments
The authors acknowledge the Victorian Partnership for
Advanced Computing (VPAC) for providing computing
facilities. The authors also formally thank the anonymous
reviewers for their constructive suggestions.References
[1] Lavine BK, Davidson CE, Rayens WS. Machine learning based
pattern recognition applied to microarray data. Comb Chem High
Throughput Screening 2004;7:115–31.
[2] Sehgal MSB, Gondal I, Dooley L. A collimator neural network
model for the classiﬁcation of genetic data. Adv Bioinform Appl
World Sci 2004;8:229–39.
[3] Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen M,
et al. Comprehensive identiﬁcation of cell cycle-regulated genes of the
yeast Saccharomyces cerevisiae by microarray hybridization. Mol
Biol Cell 1998;9:3273–97.
[4] Furey TS, Cristianini N, Duﬀy N, Bednarski DW, Schummer M,
Haussler D. Support vector machine classiﬁcation and validation of
cancer tissue samples using microarray expression data. Bioinfor-
matics 2000;16(10):906–14.
[5] Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC,
et al. Diﬀuse large B-cell lymphoma outcome prediction by gene
expression proﬁling and supervised machine learning. Nat Med
2002;8(1):68–74.
[6] Gustavo B, Monard CM. An analysis of four missing data
treatment methods for supervised learning. Appl Artif Int
2003;17(5–6):519–33.
[7] Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH,
Angelo M, et al. Multiclass cancer diagnosis using tumour gene
expression signatures. Proc Natl Acad Sci USA 2001;98(26):
15149–54.
[8] Sehgal MSB, Gondal I, Dooley L. Statistical neural networks and
support vector machine for the classiﬁcation of genetic mutations in
ovarian cancer. In: IEEE symposium on computational intelligence in
bioinformatics and computational biology (CIBCB)’04, USA; 2004.
p. 140–6.
[9] Sehgal MSB, Gondal I, Dooley L. Communal neural network for
ovarian cancer mutation classiﬁcation. In: Complex’04, Cairns,
Australia; 2004. p. 749–58.
[10] Golub TR, Slonim DK, Tamayo P, Huard C, Gaasen-beek M,
Mesirov JP, et al. Molecular classiﬁcation of cancer: class discovery
and class prediction by gene expression monitoring. Science
1999;286(5439):531–7.
[11] Munagala K, Tibshiran R, Brown PO. Cancer characterization and
feature set extraction by discriminative margin clustering. BMC
Bioinform 2004;5:21.
[12] Sehgal MSB, Dooley L, Gondal I, Coppel R. Coalesce gene
regulatory network reconstruction: a cross-platform transcriptional
gene network fusion framework. IEEE-TENCON 2006:1–4.
[13] Tuikkala J, Elo L, Nevalainen OS, Aittokallio T. Improving missing
value estimation in microarray data with gene ontology. Bioinfor-
matics, 2005. doi:10.1093/bioinformatics/btk019.
[14] Oba S, Sato MA, Takemasa I, Monden M, Matsubara K, Ishii S. A
Bayesian missing value estimation method for gene expression proﬁle
data. Bioinformatics 2003;19:2088–96.[15] Jornsten R, Wang H-Y, Welsh WJ, Ouyang M. DNA microarray
data imputation and signiﬁcance analysis of diﬀerential expression.
Bioinformatics 2005;21:4155–61. doi:10.1093/bioinformatics/bti638.
[16] Sehgal MSB, Gondal I, Dooley L. CF-GeNe: fuzzy framework
for robust gene regulatory network inference. J Comp
2006;7:1–8.
[17] Eschrich S, Yeatman TJ. DNA microarrays and data analysis: an
overview. Surgery 2004;136:500–3.
[18] Sehgal MSB, Gondal I, Dooley L. K-ranked covariance based
missing values estimation for microarray data classiﬁcation. IEEE
Hybrid Intell Syst (HIS)’04, Japan 2004:274–9.
[19] Acuna E, Rodriguez C. The treatment of missing values and its eﬀect
in the classiﬁer accuracy. Class Cluster Data Mining Appl
2004:639–48.
[20] Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T,
Tibshirani R, et al. Missing value estimation methods for DNA
microarrays. Bioinformatics 2001;17:520–5.
[21] Sehgal MSB, Gondal I, Dooley L. A collateral missing value
estimation algorithm for DNA microarrays. In: IEEE international
conference on acoustics, speech, and signal processing (ICASSP),
USA; 2005. p. 377–80.
[22] Bø TH, Dysvik B, Jonassen I. LSimpute: accurate estimation of
missing values in microarray data with least squares methods. Nucleic
Acids Res 2004;32(3):e34.
[23] Sehgal MSB, Gondal I, Dooley L. Collateral missing value imputa-
tion: a new robust missing value estimation algorithm for microarray
data. Bioinformatics 2005;21(10):2417–23.
[24] Casella G, Robert CP. Monte Carlo statistical methods. Springer;
2005.
[25] Amir AJ, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET.
Gene expression proﬁles of BRCA1-linked, BRCA2-linked, and
sporadic ovarian cancers. J Nat Cancer Inst 2002;94(13).
[26] Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon
R, et al. Gene-expression proﬁles in hereditary breast cancer. N Engl
J Med 2001;344(8):539–48 [p. 22].
[27] Matsumoto R, Akama K, Rakwal R, Iwahashi H. The stress
response against denatured proteins in the deletion of cytosolic
chaperones SSA1/2 is diﬀerent from heat-shock response in
Saccharomyces cerevisiae. BMC Genomics 2005;6:141.
[28] Sidak Z, Sen PK, Hajek J. Theory of rank tests (probability and
mathematical statistics). Academic Press; 1999.
[29] Ouyang M, Welsh WJ, Georgopoulos P. Gaussian mixture clustering
and imputation of microarray data. Bioinformatics
2004;20(6):917–23.
[30] Kim H, Golub GH, Park H. Missing value estimation for DNA
microarray gene expression data: local least squares imputation.
Bioinformatics 2005;21:187–98. doi:10.1093/bioinformatics/bth499.
[31] Abelson RP. Statistics as principled argument. Lawrence Erlbaum
Associates; 1995.
[32] Chen PY, Popovich PM. Correlation: parametric and nonparametric
measures. 1st ed. SAGE Publications; 2002.
[33] Harvey M, Arthur C. Fitting models to biological data using linear
and nonlinear regression. Oxford University Press; 2004.
[34] Cooper GM, Hausman RE. The cell: a molecular approach. 4th
ed. ASM Press and Sinauer Associates, Inc.; 2006.
[35] Salceda S, Drumright C, DiEgidio A, Liang B, Hu P, Sun Y, et al.
Identiﬁcation of diﬀerentially expressed genes in breast cancer. Nat
Genet 2001;27:83–4.
[36] Bø TH, Jonassen I. New feature subset selection procedures for
classiﬁcation of expression proﬁles. Genome Biol 2002;3(4).
[research0017.1-research0017.11].
[37] Harvell DME, Richer JK, Allred DC, Sartorius CA, Horwitz KB.
Estradiol regulates diﬀerent genes in human breast tumor xenografts
compared with the identical cells in culture. Endocrinology
2006;147:700–13. doi:10.1210/en.2005-0617.
[38] Mertens C, Kuhn C, Franke W. Plakophilins 2a and 2b: constitutive
proteins of dual location in the karyoplasm and the desmosomal
plaque. J Cell Biol 1996;135:1009–25. doi:10.1083/jcb.135.4.1009.
514 Muhammad Shoaib B. Sehgal et al. / Journal of Biomedical Informatics 41 (2008) 499–514[39] Mertens C, Kuhn C, Moll R, Schwetlick I, Franke WW. Desmo-
somal plakophilin 2 as a diﬀerentiation marker in normal and
malignant tissues. Diﬀerentiation 1999;64:277–90. doi:10.1046/j.1432-
0436.1999.6450277.x.
[40] Jansen E, Laven JSE, Dommerholt HBR, Polman J, van Rijt C, van
den Hurk C, et al. Abnormal gene expression proﬁles in humanovaries from polycystic ovary syndrome patients. Mol Endocrinol
2004;18:3050–63. doi:10.1210/me.2004-0074.
[41] Lu M, Thompson WA, Lawlor DA, Reveille JD, Lee JE. Rapid
direct determination of HLA-DQB1*0301 in the whole blood of
normal individuals and cancer patients by speciﬁc polymerase chain
reaction ampliﬁcation. J Immunol Methods 1996;199:61–8.
